AMDL (Tustin, California), a developer of tests for the early detection of cancer and other serious diseases, reported that it has retained the statistical and regulatory consulting firm R.P. Chiacchierini & Associates (Rockville, Maryland) to provide additional statistical analysis for the FDA to support its request for clearance to market its DR-70 cancer test kit in the U.S.
R.P. Chiacchierini & Associates reports having assisted more than 700 firms with their filings.
AMDL, a theranostics company, developedr the DR-70 non-invasive cancer blood test designed to detect the presence of up to 14 cancers 84% of the time.
Sontra regains Nasdaq compliance
Sontra Medical (Franklin, Massachusetts), focused on transdermal science, said that, following its recently completed reverse stock split, it has regained compliance with the Nasdaq Capital Market's $1 minimum bid price requirement for continued listing. On August 11, Sontra completed a 1-for-10 reverse split of its common stock and began trading under the symbol “SONT.”